Clinical Trials Logo

Stage IVB Prostate Cancer clinical trials

View clinical trials related to Stage IVB Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03805594 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 10, 2019
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating patients with castration-resistant prostate cancer that has spread to other places in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating prostate cancer.